Home      About us      Services      Case Study      Drug R & D      Products      Consulting      News
 
HBV Poster AASLD2016
STG-175 Paper on PLOS ONE, 2016
HCV Poster EASL2016
HCV Poster AASLD2015


Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/bbparser.php on line 137

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 852

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 860

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 927

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 927

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 927

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 927

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 927

Deprecated: preg_replace(): The /e modifier is deprecated, use preg_replace_callback instead in /home/stglobal/public_html/index1.php on line 953
September of 2014
Sept. 9, 2014 (GLOBE NEWSWIRE)--OnCore Biopharma, Inc. ("OnCore" or the "Company"), a biotechnology company focused on the research, development and commercialization of oral treatments for chronic hepatitis B virus (HBV) infection, announced today the exclusive worldwide license to a series of second-generation cyclophilin inhibitors for the treatment of HBV from NeuroVive Pharmaceutical AB ("NeuroVive"; STO:NVP), a leading mitochondrial medicine company located in Lund, Sweden. Under the terms of the agreement, OnCore will pay NeuroVive an initial upfront payment, development and sales milestones, and royalties based on future sales. The total value of the license agreement is up to $150 million, excluding royalty payments.


 
 

 

 

Copyright © 2009 - 2019  S & T Global, Inc. All rights reserved